Efforts to remediate Catalent, Inc’s manufacturing site in Brussels, Belgium, to address US FDA inspectional observations and restore production of Novo Nordisk A/S’s just-launched Wegovy (semaglutide) reflect some of the challenges manufacturers face in keeping facilities fit as they age.
Catalent describes the Brussels plant as its flagship European syringe filling facility, with more than 70 years of biologics and
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?